Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss.

IF 2.3 4区 医学
Journal of Clinical Pharmacology Pub Date : 2011-04-01 Epub Date: 2010-10-12 DOI:10.1177/0091270010369241
Christine Redon, Christophe Lopez, Laurence Bernard-Demanze, Michel Dumitrescu, Jacques Magnan, Michel Lacour, Liliane Borel
{"title":"Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss.","authors":"Christine Redon,&nbsp;Christophe Lopez,&nbsp;Laurence Bernard-Demanze,&nbsp;Michel Dumitrescu,&nbsp;Jacques Magnan,&nbsp;Michel Lacour,&nbsp;Liliane Borel","doi":"10.1177/0091270010369241","DOIUrl":null,"url":null,"abstract":"<p><p>Vestibular loss induces a combination of postural, oculomotor, and perceptive symptoms that are compensated over time. The aim of this study was to analyze the influence of betahistine dihydrochloride on vestibular compensation. A randomized, double-blind, placebo-controlled study was performed in Menière's disease patients who underwent a curative unilateral vestibular neurotomy (UVN). The effects of betahistine treatment were investigated on a broad spectrum of vestibular-induced changes resulting from vestibular loss: body sway, head orientation, ocular cyclotorsion, spontaneous nystagmus, verticality perception, and self-evaluation of the postural stability. The time course of the recovery was compared in 16 patients who received either a placebo or betahistine (24 mg b.i.d.) from 3 days up to 3 months after UVN. Patients were examined before (day -1) and after UVN (days 7, 30, and 90). Results indicate that betahistine reduces the time to recovery by 1 month or more depending on the tested functions. Betahistine was effective as soon as 4 days after treatment administration, and the effect remained during the whole compensation period (up to 3 months). The observed clinical effects may be attributed to an action of betahistine in rebalancing the neuronal activity between contralateral vestibular nuclei.</p>","PeriodicalId":48908,"journal":{"name":"Journal of Clinical Pharmacology","volume":"51 4","pages":"538-48"},"PeriodicalIF":2.3000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/0091270010369241","citationCount":"47","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/0091270010369241","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2010/10/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 47

Abstract

Vestibular loss induces a combination of postural, oculomotor, and perceptive symptoms that are compensated over time. The aim of this study was to analyze the influence of betahistine dihydrochloride on vestibular compensation. A randomized, double-blind, placebo-controlled study was performed in Menière's disease patients who underwent a curative unilateral vestibular neurotomy (UVN). The effects of betahistine treatment were investigated on a broad spectrum of vestibular-induced changes resulting from vestibular loss: body sway, head orientation, ocular cyclotorsion, spontaneous nystagmus, verticality perception, and self-evaluation of the postural stability. The time course of the recovery was compared in 16 patients who received either a placebo or betahistine (24 mg b.i.d.) from 3 days up to 3 months after UVN. Patients were examined before (day -1) and after UVN (days 7, 30, and 90). Results indicate that betahistine reduces the time to recovery by 1 month or more depending on the tested functions. Betahistine was effective as soon as 4 days after treatment administration, and the effect remained during the whole compensation period (up to 3 months). The observed clinical effects may be attributed to an action of betahistine in rebalancing the neuronal activity between contralateral vestibular nuclei.

倍他司汀治疗可改善单侧前庭功能丧失患者静态症状的恢复。
前庭功能丧失可引起体位、动眼病和知觉症状的组合,这些症状可随时间补偿。本研究的目的是分析盐酸倍他司汀对前庭代偿的影响。一项随机、双盲、安慰剂对照研究对接受单侧前庭神经切开术(UVN)治疗的meni病患者进行了研究。我们研究了倍他司汀对前庭功能丧失引起的前庭功能改变的影响:身体摇摆、头部定向、眼球旋转扭转、自发性眼球震颤、垂直感和姿势稳定性的自我评价。从UVN后3天到3个月,比较了16例接受安慰剂或倍他司汀(每日24毫克)的患者的恢复时间过程。分别在UVN前(第1天)和后(第7、30和90天)对患者进行检查。结果表明,倍他司汀可根据测试功能缩短1个月或更多的恢复时间。倍他司汀在给药后第4天即有效,且在整个补偿期(长达3个月)均有效。观察到的临床效果可能归因于倍他司汀在平衡对侧前庭核之间的神经元活动中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Pharmacology
Journal of Clinical Pharmacology PHARMACOLOGY & PHARMACY-
自引率
3.40%
发文量
0
期刊介绍: The Journal of Clinical Pharmacology (JCP) is a Human Pharmacology journal designed to provide physicians, pharmacists, research scientists, regulatory scientists, drug developers and academic colleagues a forum to present research in all aspects of Clinical Pharmacology. This includes original research in pharmacokinetics, pharmacogenetics/pharmacogenomics, pharmacometrics, physiologic based pharmacokinetic modeling, drug interactions, therapeutic drug monitoring, regulatory sciences (including unique methods of data analysis), special population studies, drug development, pharmacovigilance, womens’ health, pediatric pharmacology, and pharmacodynamics. Additionally, JCP publishes review articles, commentaries and educational manuscripts. The Journal also serves as an instrument to disseminate Public Policy statements from the American College of Clinical Pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书